# About KLOW Safe — Independent Editorial Project > KLOW Safe is an independent editorial project that summarizes peer-reviewed research on the four-peptide KLOW blend. Not a clinic. Not a vendor. Editorial commentary on publicly available science. KLOW Safe summarizes the peer-reviewed research literature on the four-peptide KLOW blend. We do not employ clinicians, do not provide medical advice, and do not sell anything. ## What this project is KLOW Safe is an independent editorial project that publishes summaries of the peer-reviewed research literature on the KLOW research-peptide blend (GHK-Cu + BPC-157 + TB-500 + KPV). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The domain name reads as a safety claim — KLOW Safe — but the word 'safe' here is the editorial question the site asks, not an assertion that the blend is safe for any particular use. The site exists because the question is asked frequently in search and because the answer in the peer-reviewed literature is more nuanced than either vendor copy or anti-peptide advocacy suggests. The honest answer requires reading each component on its own terms and then reading the gap that the combination has never been studied. ## Editorial standards Every quantitative claim on this site cites a peer-reviewed study, a regulatory document, or a recognized clinical-trial registry. The full list of sources is on the [references page](/references). We use PubMed, PubMed Central, ClinicalTrials.gov, FDA materials, and journal-published primary sources. We do not cite Reddit, YouTube, vendor blog posts, or anonymous forum discussion as evidence of biological effect. We distinguish carefully between species. Rodent data is labeled as rodent data. In-vitro data is labeled as in-vitro data. Human clinical data is labeled as such — and where it exists, we report the trial phase, the sample size, and the route of administration. We never present a rodent finding as if it were a human one. We distinguish between the TB-500 7-amino-acid fragment and full-length 43-amino-acid Thymosin Beta-4. The two molecules are often conflated; we treat them as separate evidence bases because the clinical safety data does not transfer cleanly between them. We distinguish between single-agent data and combination data. The KLOW blend has never been studied as a four-peptide combination. Every safety inference for the blend is an extrapolation from single-agent literature, and we mark it as such. ## What this project is not We are not a clinic, telehealth service, or medical practice. We do not employ physicians, pharmacists, nurses, or other clinical staff. We do not offer consultations, evaluations, or prescriptions. We do not have a clinical team, a medical director, or a 'our doctors' page — because no such people exist at this project. We are not a vendor. We do not sell research peptides, blends, vials, or any other product. We do not receive commissions from peptide vendors. We do not have affiliate relationships with research-supply companies. We are not paid by any laboratory or manufacturer. We are not a regulator. Nothing on this site should be read as an enforcement position, a legal opinion, or a compliance review. We describe the regulatory status of each component as documented in publicly available FDA and WADA materials, and we link to those primary documents. The domain name and the word 'safe' in it are editorial framing — a position the publisher occupies relative to the literature — not a claim about the site's services or about the blend's safety in human use. ## Regulatory status reference The blend's components carry the following regulatory designations as of the most recent publicly available materials: - **BPC-157.** FDA Category 2 (Substances with Safety Concerns); ineligible for pharmacy compounding [17]. WADA Prohibited List S0 [22]. - **GHK-Cu.** Permitted in topical cosmetics. Injectable form not FDA-approved for any indication. - **TB-500.** Not FDA-approved. WADA Prohibited List S2. Distinct from full-length Thymosin Beta-4. - **KPV.** Not FDA-approved. No specific WADA listing as of the current Prohibited List; the S0 catch-all may apply for athletes. This is reproduced from the [safety page](/safety) for visitors arriving directly at /about. The full regulatory discussion lives there. ## How to contact us The [contact page](/contact) has a form for editorial corrections, citation suggestions, or questions about the methodology. We do not respond to medical questions, dosing questions, or sourcing questions — those are outside what an editorial project can helpfully answer. If you believe a study citation on this site is mischaracterized, broken, or out of date, please let us know via the contact form. --- Editorial commentary on peer-reviewed research — not a clinic, not a vendor, not a prescription.